AC Immune SA ACIU.OQ ACIU.O is expected to show a fall in quarterly revenue when it reports results on March 12 (estimated) for the period ending December 31 2024
The Lausanne Vaud-based company is expected to report a 95.0% decrease in revenue to CHF742.09 thousand from CHF14.8 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for AC Immune SA is for a loss of 19 rappen per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AC Immune SA is $8.50, above its last closing price of $2.41.
Previous quarterly performance (using preferred earnings measure in Swiss francs).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.19 | -0.20 | 0.05 | Beat | 125.5 |
Jun. 30 2024 | 0.35 | 0.27 | -0.23 | Missed | -185.4 |
Mar. 31 2024 | -0.13 | -0.14 | -0.18 | Missed | -33.2 |
Dec. 31 2023 | -0.06 | -0.11 | -0.05 | Beat | 55.9 |
Sep. 30 2023 | -0.07 | 0.03 | -0.18 | Missed | -801.2 |
Jun. 30 2023 | -0.19 | -0.20 | -0.20 | Met | -1.4 |
Mar. 31 2023 | -0.23 | -0.23 | -0.21 | Beat | 8.5 |
Dec. 31 2022 | -0.25 | -0.23 | Beat | 8.7 |
This summary was machine generated March 10 at 12:32 GMT. All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)